title: Patients preferences in chemotherapy for advanced non-small-cell lung cancer.
abstract: OBJECTIVE
  To determine how Japanese patients with lung cancer weigh potential survival, chemotherapy response rate, and symptom relief against the potential toxicity of different treatments in cancer chemotherapy.
  
  
  METHODS
  We used a questionnaire describing a hypothetical situation about stage IV non-small-cell lung cancer. Seventy-three patients with lung cancer who had received chemotherapy and 120 patients with other respiratory disease as the control group were asked to rate the minimal benefit that would make two hypothetical treatments acceptable. For "chance of cure," "response but not cure," and "symptom relief," the subjects could give answers from 1% to 100% and for prolonging life could give answers from 1 to 60 months.
  
  
  RESULTS
  Patients with lung cancer were significantly more likely than were patients with other respiratory diseases to accept either intensive or less-intensive treatments for a potentially small benefit for "chance of cure," "response but not cure," and "symptom relief". The degree of survival advantage that patients require before accepting cancer treatment with its associated toxicity varied widely. If their lives were prolonged 3 months, 19% and 21% of patients with lung cancer would choose to receive intensive and less-intensive treatment, respectively. When the chance of symptom relief was 70%, 73% of patients with lung cancer were willing to choose intensive chemotherapy. Factor associated with patients' choice of chemotherapy in both groups was age.
  
  
  CONCLUSIONS
  Oncologists must consider the substantial range of attitudes to chemotherapy among patients when making treatment decisions and they must give patients the opportunity to be included in this process.
authors.affiliation: First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666.
authors.forename: Takashi
authors.initials: T
authors.lastname: Hirose
authors.forename: Naoya
authors.initials: N
authors.lastname: Horichi
authors.forename: Tohru
authors.initials: T
authors.lastname: Ohmori
authors.forename: Sohjiroh
authors.initials: S
authors.lastname: Kusumoto
authors.forename: Tomohide
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Takao
authors.initials: T
authors.lastname: Shirai
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Ozawa
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Adachi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000523:psychology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017060:Patient Satisfaction; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents